▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Cheryl Swanson

CherylSwanson

Cheryl has six books published, and currently resides in Hawaii with her husband, her daughter and two dozen surfboards. With a 20-year background as a former medical technology and management consultant, as well as a cancer survivor, Cheryl has a unique perspective on health care. Follow her on Twitter at @uthorcdswanson

Recent Articles by Cheryl Swanson

Sep 2, 2014 by Cheryl Swanson

3 Things Baxter International Inc.'s Management Wants You to Know

With global expansion of Advate and European approval of a $370 million new production facility in Singapore, Baxter is diving headfirst into its future. Here's why executives believe this company is about to fundamentally change for the better.

Aug 15, 2014 by Cheryl Swanson

5 Things UnitedHealth Group Inc.'s Management Wants You to Know

UnitedHealth is evolving rapidly, trying to get ahead of the titanic shifts caused by Affordable Care. But investors need to know--will the company retain its competitive edge?

Aug 13, 2014 by Cheryl Swanson

3 Reasons Baxter International Inc.'s Stock Could Rise

This global healthcare company is slimming down while preparing for its forthcoming split. And it's finding surprising ways to unlock value for shareholders.

Jul 28, 2014 by Cheryl Swanson

Can HCA Holdings, inc. Stock Keep Growing?

HCA went lean in anticipation of health reform, and is now getting fat on increasing ranks of insured. But gains for this stock and others could go up in smoke in 2014 if Obamacare subsidies are gutted

Jul 23, 2014 by Cheryl Swanson

Gilead Stock's Great Expectations and Giant Opportunity

Gilead Sciences raked in a massive $3.48 billion from its wonder drug Sovaldi, trouncing Q2 consensus estimates. So why did this stock drop?.

Jul 21, 2014 by Cheryl Swanson

Welcome to Ireland, AbbVie

AbbVie paid a whopping $54.8 billion for Shire, but it's a good deal--assuming the U.S. Congress doesn't pass a law undercutting the tax gains.

Jul 20, 2014 by Cheryl Swanson

Alzheimer's Needs Cures, Not Pyrrhic Victories

As the world's largest Alzheimer's research conference kicks off in Denmark, finding a cure is a long shot at best. Still, there are companies worth watching in this space.

Jul 18, 2014 by Cheryl Swanson

UnitedHealth: Bigger is Better, Except When It's Not

Stung by declining enrollment, the insurance giant says it is about to jump into the Obamacare exchanges, but competition will be fierce this time around.

Jul 16, 2014 by Cheryl Swanson

Keep Calm and Carry On, J&J

Thanks to J&J's new drugs, the company's Q2 earnings were solid. But a jittery market focused on the bad news.

Jul 11, 2014 by Cheryl Swanson

How UnitedHealth Can Impress Next Quarter

Will UnitedHealth continue its path to greatness, or will management's over-cautious approach to the healthcare reform derail its future performance?

Jul 7, 2014 by Cheryl Swanson

The Revolt Against Big Pharma's Astronomical Prices

As pharmacy benefits manager ramp up efforts to rein in soaring drug prices, companies like Glaxo and Pfizer are seeing precipitous drops in sales of key drugs

Jul 1, 2014 by Cheryl Swanson

Is this Biogen's Biggest Risk?

With peak sales of its blockbuster MS drug pegged at $3.8 billion, and two new drugs in the hemophilia market, what could derail this stock from liftoff this year?

Jun 30, 2014 by Cheryl Swanson

1 Critical Question Swirling Around Medtronic's Mega-Merger

Medtronic's bid to buy itself better tax rate stirred up a political firestorm in the U.S., but does it make sense for stockholders?

Jun 25, 2014 by Cheryl Swanson

Will Shire's Growth Plan Motivate AbbVie to Dig Deeper?

Shire fended off AbbVie's most recent offer by doubling sales targets to $10 billion by 2020, but a better offer may be coming.

Jun 17, 2014 by Cheryl Swanson

2 Exciting Developments for Biogen Idec Inc.

With a blockbuster drug for hemophilia about to launch amid little fanfare, and a new drug for MS, Biogen could be underappreciated by the Street.

Jun 16, 2014 by Cheryl Swanson

Johnson & Johnson Scores a Solid Hit With Imbruvica

J&J knows how to make great deals come together, but will it pay off for investors?

Jun 13, 2014 by Cheryl Swanson

Is this Gilead's Biggest Risk?

Gilead looks gilded right now, but could the company's huge success threaten its future?

Jun 11, 2014 by Cheryl Swanson

ASCO 2014: Competition Heats Up

Bristol, Merck, Roche and AstraZeneca all boast drugs that are turning cancer into a chronic disease, or even eradicating it entirely, while some analysts look the other way.

Jun 7, 2014 by Cheryl Swanson

From Obamacare to Fitness Apps, 3 Profit-Boosting Ideas

Cigna, Aetna and Wellpoint raised their profit forecasts recently. The major insurers cost-cutting and profit-boosting efforts include deals with technology companies, hospitals and oncologists. But the agreements are raising eyebrows and may not spell good news for long-term investors.

Jun 3, 2014 by Cheryl Swanson

Bargains in Biotech? Yes, They Exist

Looking for value for your money in biotech stocks? A new set of metrics for valuing biotechnology companies created by a long-time Wall Street analyst could be a game-changer.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services